A Multi-Center, Single-Arm, Phase II Study of Vorinostat (V) in Combination With Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) Followed by VB Maintenance in Patients With Relapsed and Relapsed/Refractory Multiple Myeloma.

Trial Profile

A Multi-Center, Single-Arm, Phase II Study of Vorinostat (V) in Combination With Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) Followed by VB Maintenance in Patients With Relapsed and Relapsed/Refractory Multiple Myeloma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 May 2012

At a glance

  • Drugs Bortezomib; Doxorubicin liposomal; Vorinostat
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2012 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Actual initiation date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top